BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Thyroid CancerUnresectable Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma+ [10]

Inactive Indication

Acinar Cell CarcinomaAcute Biphenotypic Leukemiaacute leukemia+ [142]

Originator Organization

Onyx Pharmaceuticals, Inc.

Active Organization

Disruptive Pharma AB

Accord Healthcare SL

Bayer HealthCare Pharmaceuticals, Inc.

+ [9]

Inactive Organization

Novartis AG

Amgen, Inc.

Bristol Myers Squibb Co.

+ [17]

License Organization

Amgen, Inc.

Bayer Healthcare Co., Ltd.

Onyx Pharmaceuticals, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (01 Dec 2005),

Advanced Renal Cell Carcinoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC28H24ClF3N4O6S

InChIKeyIVDHYUQIDRJSTI-UHFFFAOYSA-N

CAS Registry475207-59-1

863

Clinical Trials associated with Sorafenib Tosylate

ChiCTR2600120015

/ Not yet recruitingNot ApplicableIIT

Single-Center Prospective Study of Homoharringtonine Combined with Azacitidine and Venetoclax in the Treatment of Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Start Date08 Mar 2026

Sponsor / Collaborator

The First Hospital Of China Medical University

NCT06227221

/ Not yet recruitingPhase 2IIT

A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.

Start Date01 Feb 2026

Sponsor / Collaborator

The Third Xiangya Hospital of Central South University

NCT07264010

/ Not yet recruitingPhase 2/3IIT

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Start Date01 Dec 2025

Sponsor / Collaborator

Nanfang Hospital

100 Clinical Results associated with Sorafenib Tosylate

100 Translational Medicine associated with Sorafenib Tosylate

100 Patents (Medical) associated with Sorafenib Tosylate

14,157

Literatures (Medical) associated with Sorafenib Tosylate

31 Dec 2026·ANNALS OF MEDICINE

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis

Review

Author: E., Shaolong ; Ying, Tianshu ; Ying, Huanchun

BACKGROUND:

Although single-agent chemotherapy is the most common approach for treating platinum-resistant or refractory ovarian cancer (PROC), there is growing evidence that combining molecular targeted agents with chemotherapy is beneficial, especially for certain patient groups. However, the most effective combination regimen remains elusive.

OBJECTIVES:

This Bayesian network meta-analysis (NMA) aims to identify the best combination therapy for PROC.

METHODS:

Relevant studies were searched in PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials from their inception until October 2024. The primary outcomes were overall survival (OS), progression-free survival (PFS) and adverse events (AEs). Statistical analyses were performed using the GEMTC package (1.0-2) and R 4.2.0. This review was registered in PROSPERO (CRD42023428414).

RESULTS:

Our analysis of 22 randomized controlled trials (RCTs) (n = 3408) demonstrated that chemotherapy combinations with bevacizumab (hazard ratio (HR) = 0.52-0.65), sorafenib (HR = 0.65, 95% confidence interval (CI): 0.45-0.93) or adavosertib (HR = 0.56, 95%CI: 0.35-0.90) significantly improved OS and PFS versus chemotherapy alone. Notably, adavosertib + gemcitabine was associated with an increased risk of grade 3-4 AEs (relative risk (RR) = 1.8, 95%CI: 1.3-2.7), but these were generally manageable.

CONCLUSIONS:

Bevacizumab-based combinations demonstrate consistent benefits across multiple regimens for PROC. Paclitaxel + bevacizumab emerges as the optimal balance of efficacy and safety. Topotecan + sorafenib could be an alternative for patients who are ineligible for anti-angiogenic therapy.

01 Dec 2026·FUNCTIONAL & INTEGRATIVE GENOMICS

Overexpression, clinical significance and potential mechanisms of protein kinase D1 in hepatocellular carcinoma: multi-omic analyses and pharmacological insights

Article

Author: He, Rong-Quan ; Huang, Zhi-Guang ; Chen, Zhen-Dong ; Deng, Yu-Long ; Dang, Yi-Wu ; Wei, Xi-Ni ; Zhu, Liang-Qin ; Yang, Min-Ying ; Chen, Gang ; Wu, Ke-Jun ; He, Fei-Yan ; Zhan, Yan-Ting ; Qin, Kai ; Tang, Yu-Xing ; Lu, Hui-Ping

Protein kinase D1 (PRKD1), a serine/threonine kinase of the PKD family, has been implicated in tumor biology, but its role in hepatocellular carcinoma (HCC) remains unclear. We explored PRKD1 expression and function using immunohistochemistry, bulk and single-cell RNA sequencing, and in vitro functional assays. PRKD1 protein levels were significantly elevated in 339 HCC tissues compared to corresponding adjacent non-tumorous samples (11.390 ± 1.560 vs. 6.277 ± 2.357, P < 0.0001). Multicenter bulk transcriptomic data confirmed consistent PRKD1 mRNA overexpression (SMD = 0.26, 95% CI = 0.14-0.39), with single-cell transcriptomic profiling indicating specific enrichment in endothelial cells, smooth muscle cells, and hepatocytes. High PRKD1 expression was associated with advanced tumor stages and worse overall survival. Functionally, PRKD1-associated genes were enriched in extracellular matrix and focal adhesion pathways. Immune profiling revealed positive correlations with M2 macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), and negative correlations with CD8⁺ T cells and CD4⁺ Th1 cells, suggesting an immunosuppressive role. Mechanistic experiments demonstrated that conditioned medium from PRKD1-knockdown HCC cells promoted M1 polarization and reduced M2 markers in THP-1 cells, while PRKD1 silencing increased PD-L1 and IDO1 expression. In contrast, IFN-γ treatment did not induce PRKD1 expression, indicating that PRKD1 actively contributes to, rather than responds to, immunosuppressive cues. PRKD1 knockdown markedly impaired HCC cell proliferation and migration. Pharmacologically, nitidine chloride significantly reduced PRKD1 expression in a dose-dependent manner, and molecular docking suggested a potential direct interaction. With respect to drug response, PRKD1-high HCC cases exhibited increased predicted sensitivity to multiple tyrosine kinase inhibitors (TKIs), while in vitro PRKD1 knockdown reduced sorafenib sensitivity, and sorafenib treatment suppressed both PRKD1 and p-ERK1/2 levels. Collectively, our findings identify PRKD1 as a multifaceted contributor to HCC progression, immune microenvironment modulation, and TKI responsiveness. These results highlight PRKD1 as a promising therapeutic target warranting further mechanistic and translational investigation.

01 Jun 2026·BIOORGANIC CHEMISTRY

Novel benzophenones from the fibrous roots of Anemarrhena asphodeloides Bunge inhibit hepatocellular carcinoma activity by targeting ALDH3A1

Article

Author: Huang, Qi ; Chen, Fang-Fang ; Xu, Feng-Qing ; Liao, Zhen-Dong ; Wu, De-Ling ; Ren, Fu-Cai ; Wang, Ren-Zhong ; Zhao, Hong-Su

Hepatocellular carcinoma (HCC) represents a formidable clinical challenge due to limited treatment options. Plant-derived natural products, in particular, represent a promising source for such discoveries. The fibrous roots of Anemarrhena asphodeloides Bunge (FRA) were subjected to investigation. Six novel benzophenone derivatives (Anemarrhenones A-F) and six known compounds were isolated and identified. Anemarrhenone A (AA), with IC₅₀ values of 5.19 ± 1.25 μM for Hep3B cells and 4.02 ± 1.13 μM for HepG2 cells, exhibited anti-HCC activity comparable to that of sorafenib (IC₅₀ of 5.63 ± 0.27 μM for Hep3B cells and 2.34 ± 0.28 μM for HepG2 cells). ALDH3A1 emerged as a direct functional target through which AA exerted its anti-HCC activity. This research revealed a potential tumor suppressive pathway mediated by AA and provided a strategic approach against HCC.

505

News (Medical) associated with Sorafenib Tosylate

22 Apr 2026

·www.prnewswire.com

Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2α-biased bispecific fusion protein) * as well as TYVYT® (sintilimab injection)** will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026, in Chicago, Illinois, U.S. Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, stated: "We are excited to announce that at the 2026 ASCO Annual Meeting, we will present new PoC data of IBI363 in NSCLC, across both IO-resistant and first-line settings. With robust PoC data for IO-resistant NSCLC now in hand, we are moving IBI363 into MRCT pivotal development, an important step toward tackling a major global unmet medical need. At the same time, we are encouraged by the promising dose optimization data in first-line NSCLC, and we look forward to continued maturation of PoC full data to inform our next steps. Innovent will continue to push the boundaries of cancer care, as we are dedicated to delivering physicians and patients more innovative, effective, and life-saving treatment options." Abstracts of IBI363(PD-1/IL-2 α -biased bispecific fusion protein) 1. Presentation Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC). Abstract Number: 8586 Session Type: Poster Session Title: Lung Cancer/Non-Small Cell Metastatic Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT Presenter: Dr. Haiyan Tu, Guangdong Provincial People's Hospital 2. Presentation Title: First-in-class PD-1/IL-2α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC): updated results from a phase I study. Abstract Number: 2618 Session Type: Poster Session Title: Developmental Therapeutics/Immunotherapy Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT Presenter: Dr. Jianya Zhou, First Affiliated Hospital of Zhejiang University School of Medicine 3. Presentation Title: Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO). Abstract Number: TPS8673 Session Type: Poster Session Title: Lung Cancer/Non-Small Cell Metastatic Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT Presenter: Dr. Roy S. Herbst, Yale School of Medicine Abstracts of TYVYT®(sintilimab) 1. Presentation Title: Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2) Abstract Number: TPS4254 Session Type: Poster Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT Presenter: Dr. Yongjun Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine 2. Presentation Title: Neoadjuvant chemoradiotherapy with or without PD-1 blockade in pMMR/MSS low rectal cancer patients (CHOICE II): A multi-center, open-label, randomized controlled trial. Abstract Number: 3640 Session Type: Poster Session Title: Gastrointestinal Cancer—Colorectal and Anal Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT Presenter: Dr. Wei Zhang, Changhai Hospital 3. Presentation Title: Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study Abstract Number: 4148 Session Type: Poster Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT Presenter: Dr. Jia Fan, Zhongshan Hospital, Fudan University 4. Presentation Title: CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer. Abstract Number: TPS3680 Session Type: Poster Session Title: Gastrointestinal Cancer—Colorectal and Anal Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT Presenter: Dr. Yue Liu, The Second Affiliated Hospital of Zhejiang University School of Medicine. 5. Presentation Title: Long-term survival and biomarker analysis of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Abstract Number: 3610 Session Type: Poster Session Title: Gastrointestinal Cancer—Colorectal and Anal Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT Presenter: Dr. Xiao Weiwei, Sun Yat-sen University Cancer Center 6. Presentation Title: Larynx preservation via chemotherapy-free neoadjuvant sintilimab-cetuximab-SBRT and response-adapted treatment in locally advanced laryngeal cancer: A phase II, single-arm clinical trial (The NeoVOICE study). Abstract Number: 6095 Session Type: Poster Session Title: Head and Neck Cancer Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT Presenter: Dr. Song Ming, Sun Yat-sen University Cancer Center 7. Presentation Title: Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma. Abstract Number: LBA4082 Session Type: Poster Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT Presenter: Dr. Xuefeng Leng, Sichuan Cancer Hospital 8. Presentation Title: Sintilimab (PD-1 antibody) Plus Gemcitabine and Docetaxel (GT) as First-line or Later-line Therapy in Patients with Advanced Epithelioid Sarcoma: A Prospective, Multicenter, Single-arm, Phase II Clinical Study. Abstract Number: 11574 Session Type: Poster Session Title: Sarcoma Session Date & Time: June 1, 2026 1:30 PM-4:30 PM CDT Presenter: Dr. Xiaowei Zhang, Fudan University Shanghai Cancer Center 9. Presentation Title: Sintilimab plus Anlotinib and Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma: A Prospective, Phase II Clinical Trial. Abstract Number: 8050 Session Type: Poster Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT Presenter: Dr. Jianchun Duan, Cancer Hospital, Chinese Academy of Medical Sciences About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics 21% more press release views with Request a Demo

ASCOPhase 1Phase 2Clinical ResultPhase 3

02 Apr 2026

·firstwordpharma.com

AstraZeneca touts quadruplet approach in earlier-stage liver cancer

AstraZeneca said a treatment regimen anchored by its PD-L1 inhibitor Imfinzi (durvalumab) and anti-CTLA-4 antibody Imjudo (tremelimumab) succeeded in the Phase III EMERALD-3 trial in patients with hepatocellular carcinoma (HCC).The study is seen as an important test of whether using every available treatment strategy right from the start can improve outcomes for liver cancer patients, though some key opinion leaders (KOLs) worry such an aggressive approach may be too harsh for routine practice and could leave patients with fewer treatment options later on.EMERALD-3 includes 760 patients with unresectable, locoregional HCC who are eligible for embolisation. Participants received either the STRIDE regimen – consisting of single-dose Imjudo plus regular-interval Infinzi – with transarterial chemoembolisation (TACE); the same immunotherapy backbone plus Eisai's VEGF receptor inhibitor Lenvima (lenvatinib) and TACE; or TACE alone.Eye on OSAstraZeneca said the quadruplet approach achieved significant and clinically meaningful improvement on the primary endpoint of progression-free survival (PFS), compared to TACE alone. Overall survival (OS), a key secondary endpoint, showed a trend in favour of this combination as well, but data are still immature.Although it hasn't yet been formally tested, AstraZeneca said early data from the treatment arm that didn't receive Lenvima revealed "strong trends" toward improved PFS and OS.The trial will continue to follow OS in both investigational arms, though the company is optimistic. Susan Galbraith, head of oncology haematology R&D at AstraZeneca, said EMERALD‑3 builds on the Phase III HIMALAYA results, "where the STRIDE regimen has already demonstrated durable overall survival benefit."HIMALAYA tested the combination of Imfinzi and Imjudo in HCC patients with advanced, unresectable disease. Long-term data presented at the European Society for Medical Oncology (ESMO) conference in 2024 showed that nearly 20% of patients given the combination were alive at five years, roughly double the OS rate with Bayer's Bayer's Nexavar (sorafenib).However, earlier efforts to combine Imfinzi with TACE got a mixed reception in the Phase III EMERALD‑1 study a few years ago, where PFS benefit depended on the inclusion of Roche's Avastin (bevacizumab).Toxicity concernsMeanwhile, AstraZeneca said the safety profile for each combination in EMERALD-3 was consistent with the known profiles of each medicine, adding there were no new safety findings. More details will be shared at a forthcoming medical meeting and shared with global regulatory authorities.KOLs interviewed for a FirstWord report voiced serious concerns about toxicity especially given the aggressive use of agents targeting PD-L1, CTLA-4 and VEGF pathways in a patient population that often has cirrhosis or compromised liver function."It will be interesting to see how patients tolerate this," said one US-based KOL. "I think one of the issues with EMERALD-1 that we saw was that there were a lot of dropouts…I just wonder about the kind of additional toxicities that we might see when we keep adding therapies. That being said, you might get a prolonged response in some of these patients."

Clinical ResultPhase 3Phase 2

02 Apr 2026

·allsci.com

AstraZeneca’s durvalumab, tremelimumab combo hits PFS goals in liver cancer

AstraZeneca (LSE/STO/NYSE: AZN) reported that the combination of durvalumab (Imfinzi), tremelimumab (Imjudo), lenvatinib, and transarterial chemoembolisation met its primary endpoint in unresectable hepatocellular carcinoma eligible for embolisation, delivering a statistically significant improvement in progression-free survival versus TACE alone — a result that positions the regimen as a potential first systemic combination approved for this intermediate-stage population in the US and EU. The EMERALD-3 trial is a randomised, open-label, sponsor-blinded, multicentre Phase III study enrolling 760 patients with unresectable HCC eligible for embolisation across 171 centres in 22 countries. The trial met its primary endpoint of PFS for the four-drug combination — the STRIDE regimen (a single priming dose of tremelimumab 300mg added to durvalumab 1500mg, followed by durvalumab every four weeks) plus lenvatinib and TACE — versus TACE alone. At an interim analysis for overall survival, a key secondary endpoint, the combination also showed a trend toward OS improvement. A third arm evaluating STRIDE plus TACE without lenvatinib showed trends toward improved PFS and OS, though this comparison was not formally tested at this interim analysis. No quantitative data — hazard ratios, medians, or p-values — were disclosed. The safety profile was consistent with the known profiles of each component, with no new findings identified. Clinical context The result carries weight because it is not focused on advanced or metastatic disease. Embolisation-eligible unresectable HCC maps broadly to intermediate-stage disease — a population for which TACE has remained the standard of care for more than two decades, with most patients experiencing disease progression or recurrence within six to ten months. No systemic combination has received FDA or EMA approval specifically for this setting. The closest attempt, the LEAP-012 trial evaluating Eisai’s Lenvima (lenvatinib) plus Merck’s Keytruda (pembrolizumab) plus TACE, missed its overall survival endpoint in the global analysis, receiving approval only from China’s NMPA in 2025. The STRIDE backbone — durvalumab blocking PD-L1 to counter tumour immune evasion, combined with tremelimumab’s CTLA-4 blockade to prime T-cell activation — already holds FDA and EMA approval for advanced unresectable HCC based on the HIMALAYA Phase III trial, where it demonstrated durable OS benefit versus sorafenib. EMERALD-3 extends that immunotherapy backbone earlier in the disease course, layering in lenvatinib’s multi-kinase inhibition of VEGFR and FGFR pathways alongside locoregional TACE. The mechanistic logic is that TACE-induced tumour antigen release may enhance the immunogenic response primed by dual checkpoint blockade, while lenvatinib’s anti-angiogenic activity addresses vascular escape. Competitive context The competitive landscape in HCC has grown crowded at the advanced end. Atezolizumab plus bevacizumab (Roche) and nivolumab plus ipilimumab (Bristol Myers Squibb) are both approved for first-line advanced or metastatic HCC, and the dual PD-1/CTLA-4 class that BMS occupies is mechanistically adjacent to STRIDE. Cross-trial comparisons are limited by differences in patient populations, staging, and trial design, but EMERALD-3 targets a distinct disease stage where no approved systemic option currently exists in the US or EU — a differentiation that is structural rather than merely incremental. AstraZeneca estimates more than 200,000 patients will be eligible for embolisation in 2026. The press release notes that AstraZeneca is in discussions with global regulatory authorities. Full data are to be presented at a forthcoming medical meeting, where the magnitude of the PFS benefit and the shape of the OS curves will be made public. The STRIDE-plus-TACE arm without lenvatinib will also be watched: if its unplanned trends toward improvement hold in formal testing, it could offer a chemotherapy-free locoregional-plus-immunotherapy option for patients who may not tolerate a TKI. What EMERALD-3 does not yet answer is whether the PFS gain translates to the survival benefit that would cement a label change. Intermediate-stage HCC trials have historically struggled to convert locoregional control into OS improvements, partly because salvage options after TACE failure are varied and can confound survival analyses. The interim OS trend is directionally consistent but not yet definitive. AstraZeneca has indicated the trial will continue to follow OS and other key secondary endpoints in both investigational arms. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3ImmunotherapyDrug ApprovalClinical Study

100 Deals associated with Sorafenib Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
D06272	Sorafenib Tosylate	L01XE05	DB00398

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thyroid Cancer	United States	Bayer HealthCare Pharmaceuticals, Inc.	22 Nov 2013
Unresectable Hepatocellular Carcinoma	United States	Bayer HealthCare Pharmaceuticals, Inc.	16 Nov 2007
Advanced Hepatocellular Carcinoma	Australia	Bayer Australia Ltd.	27 Sep 2006
Differentiated Thyroid Gland Carcinoma	European Union	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Iceland	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Norway	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	European Union	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Iceland	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Norway	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	European Union	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Iceland	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Norway	Bayer AG	19 Jul 2006
Advanced Renal Cell Carcinoma	United States	Bayer HealthCare Pharmaceuticals, Inc.	01 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia with FLT3/ITD Mutation	Phase 3	China	Southern Medical University	20 Jun 2015
HER2-negative breast cancer	Phase 3	United States	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	United States	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	China	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	China	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Japan	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Japan	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	Argentina	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Argentina	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	Australia	Onyx Therapeutics, Inc.	21 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05068752 (CTgov)	Phase 2	KRAS Mutant Pancreatic Cancer	10	Vemurafenib+Sorafenib	saggmyejqr = pxrmgglekt osgjrcohmr (ojpltznklm, mjvqsqtmhx - kpxgqggsfy) View more	-	30 Mar 2026
NCT03439891 (Pubmed \| JHEP Rep)	Phase 2	Hepatocellular Carcinoma	16	Sorafenib + Nivolumab	ffxebdzwfz(vtgvtychxs) = gdpjrkgcjh vfkjswqsuk (hbxpdkargs ) View more	Negative	01 Mar 2026
NCT01893099 (Pubmed \| Br J Cancer)	Phase 1	Uveal Melanoma	10	Sorafenib plus selective internal radiotherapy with 90Y resin microspheres	ihyvpdwppg(ccjdjxsekd) = The most common grade 2-4 adverse events included rash, abdominal pain, fatigue and lymphocytopenia. dbcxyaleub (emhpjzvxch )	Negative	20 Feb 2026
NCT05068752 (Pubmed \| J Immunother Precis Oncol)	Phase 2	KRAS Mutant Pancreatic Cancer KRAS mutations	9	Vemurafenib and Sorafenib combination	rihijyizts(wfkowwrndt) = odxyekjumu oebecmbard (vfqvunqvow ) View more	Negative	10 Feb 2026
KSCC HAMRET (ASCO_GI2026)	Not Applicable	Unresectable Hepatocellular Carcinoma First line	167	Sorafenib	gvlkunqeqk(ysjyysbsws) = tuxnddjkkx wjulnznjsv (meathbtful ) View more	Positive	08 Jan 2026
				Lenvatinib	gvlkunqeqk(ysjyysbsws) = cewsvyqiyp wjulnznjsv (meathbtful ) View more
NCT05404516 (ASH2025)	Phase 2	Myeloid Sarcoma	71	Sorafenib combined with standard chemotherapy	eujwnxstcs(psvqvihwec) = pfrcpmugbl lcynxnypnp (zrewbbbfhv ) View more	Positive	06 Dec 2025
				Standard chemotherapy	eujwnxstcs(psvqvihwec) = upzixdwjoh lcynxnypnp (zrewbbbfhv ) View more
ASH2025	Not Applicable	Acute Myeloid Leukemia with FLT3/ITD Mutation First line FLT3-mutated	48	CLIA + Gilteritinib	blrumisprb(dtpxjgdxfe) = 17 cases for CLIA/gilt iyulrcnepk (oyvujoxqdq ) View more	Positive	06 Dec 2025
				CLIA + Sorafenib
ESMO_ASIA2025	Not Applicable	Unresectable Hepatocellular Carcinoma First line	3,222	Lenvatinib	iwsgzyzozm(leeoixidyi): HR = 0.98 (95.0% CI, 0.24 - 4.1)	Positive	05 Dec 2025
				Atezolizumab+Bevacizumab
NCT01377025 (STREAM, Pubmed \| iScience)	Phase 2	Uveal Melanoma First line GNAQ \| GNA11	78	Sorafenib	nahdulfnjc(oeiduddsjb) = kqbeyashpb gxwqubeibb (qbavzbhivz )	Positive	01 Dec 2025
				Placebo	nahdulfnjc(oeiduddsjb) = zgydtjdbdc gxwqubeibb (qbavzbhivz )
SITC2025	Not Applicable	Hepatocellular Carcinoma	16	Sorafenib + Nivolumab	dhhsvmkgyr(rcgiwftbtz) = Enrichment of immunosuppressive CD14+ monocytes were observed in patients with HCC and CPB but not CPA liver disease. dyqjmygwpn (jilainkfhh )	Positive	05 Nov 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis